Nipro Diagnostics, Inc.

Nipro Diagnostics, Inc., formerly known as Home Diagnostics, Inc., was a key player in the diabetes management sector, specializing in the development and distribution of blood glucose monitoring systems and related diabetes products. Operating within the Test & Measurement Equipment and Manufacturing industries, the company focused on providing essential diagnostic tools to individuals managing diabetes. Its core mission revolved around empowering patients with reliable systems to effectively monitor their condition.

In 2016, Nipro Diagnostics, Inc. underwent a significant transition, being acquired by Sinocare and subsequently renamed Trividia Health, Inc. The company's trusted TRUE brand of blood glucose monitoring systems and diabetes supplies continues to be manufactured and sold under the Trividia Health umbrella. With an employee range of 500-1,000 employees and a single primary location, the organization maintained a focused operational footprint. For insights into the personnel driving its initiatives, one can explore Meet Nipro Diagnostics, Inc.'s team.

The company's revenue reached $37.2M, positioning it within a competitive landscape that includes major players such as Sinocare, Abbott Diabetes Care, and its successor, Trividia Health. Nipro Diagnostics, Inc.'s historical operations and product lines contributed to the broader market for diabetes care technology and manufacturing, serving the North American region with B2B and technology-focused solutions.